loadpatents
Patent applications and USPTO patent grants for Debinski; Waldemar.The latest application filed is for "molecular signature of cancer".
Patent | Date |
---|---|
Molecular Signature Of Cancer App 20220062376 - Debinski; Waldemar ;   et al. | 2022-03-03 |
Molecular signature of cancer Grant 11,207,380 - Debinski , et al. December 28, 2 | 2021-12-28 |
Multi-level Specific Targeting Of Cancer Cells App 20210395324 - Debinski; Waldemar ;   et al. | 2021-12-23 |
Multi-level specific targeting of cancer cells Grant 11,136,367 - Debinski , et al. October 5, 2 | 2021-10-05 |
Epha3 And Multi-valent Targeting Of Tumors App 20200347113 - Debinski; Waldemar ;   et al. | 2020-11-05 |
Antibodies Against Human And Canine Il-13ra2 App 20200299394 - Debinski; Waldemar ;   et al. | 2020-09-24 |
EPHA3 and multi-valent targeting of tumors Grant 10,752,667 - Debinski , et al. A | 2020-08-25 |
Antibodies against human and canine IL-13RA2 Grant 10,676,529 - Debinski , et al. | 2020-06-09 |
Multi-level Specific Targeting Of Cancer Cells App 20200095302 - Debinski; Waldemar ;   et al. | 2020-03-26 |
Induced Cell Morphology Electroporation App 20200046967 - IVEY; JILL W. ;   et al. | 2020-02-13 |
Multi-level specific targeting of cancer cells Grant 10,519,210 - Debinski , et al. Dec | 2019-12-31 |
Multi-level Specific Targeting Of Cancer Cells App 20190153057 - DEBINSKI; WALDEMAR ;   et al. | 2019-05-23 |
Nucleic acids encoding a fusion protein useful for multi-level specific targeting of cancer cells Grant 10,233,224 - Debinski , et al. | 2019-03-19 |
Epha3 And Multi-valent Targeting Of Tumors App 20180244745 - Debinski; Waldemar ;   et al. | 2018-08-30 |
Molecular Signature Of Cancer App 20180243368 - Debinski; Waldemar ;   et al. | 2018-08-30 |
Antibodies Against Human And Canine Il-13ra2 App 20180155437 - Debinski; Waldemar ;   et al. | 2018-06-07 |
EPHA3 And multi-valent targeting of tumors Grant 9,975,942 - Debinski , et al. May 22, 2 | 2018-05-22 |
Molecular signature of cancer Grant 9,974,830 - Debinski , et al. May 22, 2 | 2018-05-22 |
IL-13 receptor binding peptides Grant 9,878,013 - Debinski , et al. January 30, 2 | 2018-01-30 |
Antibodies against human and canine IL-13RA2 Grant 9,868,788 - Debinski , et al. January 16, 2 | 2018-01-16 |
Multi-level Specific Targeting Of Cancer Cells App 20180002394 - Debinski; Waldemar ;   et al. | 2018-01-04 |
Multi-level specific targeting of cancer cells Grant 9,771,404 - Debinski , et al. September 26, 2 | 2017-09-26 |
Epha3 And Multi-valent Targeting Of Tumors App 20160297863 - Debinski; Waldemar ;   et al. | 2016-10-13 |
Molecular Signature Of Cancer App 20160193289 - Debinski; Waldemar ;   et al. | 2016-07-07 |
Il-13 Receptor Binding Peptides App 20160175399 - Debinski; Waldemar ;   et al. | 2016-06-23 |
IL-13 receptor binding peptides Grant 9,296,785 - Debinski , et al. March 29, 2 | 2016-03-29 |
Molecular signature of cancer Grant 9,290,558 - Debinski , et al. March 22, 2 | 2016-03-22 |
Antibodies Against Human And Canine Il-13ra2 App 20160039938 - Debinski; Waldemar ;   et al. | 2016-02-11 |
Multi-level Specific Targeting Of Cancer Cells App 20150203557 - Debinski; Waldemar ;   et al. | 2015-07-23 |
Compounds useful for multi-level specific targeting of cancer cells Grant 9,005,600 - Debinski , et al. April 14, 2 | 2015-04-14 |
Method Of Treating Brain Tumors App 20140255471 - Gmeiner; William H. ;   et al. | 2014-09-11 |
Il-13 Receptor Binding Peptides App 20130209541 - Debinski; Waldemar ;   et al. | 2013-08-15 |
Multi-level Specific Targeting Of Cancer Cells App 20130164257 - Debinski; Waldemar ;   et al. | 2013-06-27 |
Molecular Signature Of Cancer App 20130136692 - Debinski; Waldemar ;   et al. | 2013-05-30 |
Cancer immunotherapy Grant 8,435,534 - Debinski , et al. May 7, 2 | 2013-05-07 |
Multi-level specific targeting of cancer cells with IL-13 Grant 8,362,207 - Debinski , et al. January 29, 2 | 2013-01-29 |
Molecular signature of cancer Grant 8,343,461 - Debinski , et al. January 1, 2 | 2013-01-01 |
Multi-level Specific Targeting Of Cancer Cells App 20110300099 - DEBINSKI; WALDEMAR ;   et al. | 2011-12-08 |
Cancer Immunotherapy App 20110280885 - Debinski; Waldemar ;   et al. | 2011-11-17 |
Nucleic acid cancer immunotherapy Grant 7,960,361 - Debinski , et al. June 14, 2 | 2011-06-14 |
Antibody Cancer Immunotherapy App 20110110955 - Debinski; Waldemar ;   et al. | 2011-05-12 |
Nucleic acids encoding IL13 mutants Grant 7,598,058 - Debinski , et al. October 6, 2 | 2009-10-06 |
Molecular Signature Of Cancer App 20090123371 - Debinski; Waldemar ;   et al. | 2009-05-14 |
Antibody Cancer Immunotherapy App 20080206255 - Debinski; Waldemar ;   et al. | 2008-08-28 |
Fra-1 Expression In Brain Cancer App 20080188438 - Debinski; Waldemar ;   et al. | 2008-08-07 |
Nucleic Acid Cancer Immunotherapy App 20080166374 - Debinski; Waldemar ;   et al. | 2008-07-10 |
Cancer Immunotherapy App 20080131448 - Debinski; Waldemar ;   et al. | 2008-06-05 |
Cancer immunotherapy Grant 7,338,929 - Debinski , et al. March 4, 2 | 2008-03-04 |
Eph receptor tumor biomarkers App 20060121539 - Debinski; Waldemar ;   et al. | 2006-06-08 |
Fra-1 expression in brain cancer App 20050260649 - Debinski, Waldemar ;   et al. | 2005-11-24 |
Fra-1 expression in brain cancer App 20050255510 - Debinski, Waldemar ;   et al. | 2005-11-17 |
Fra-1 expression in brain cancer App 20050255511 - Debinski, Waldemar ;   et al. | 2005-11-17 |
Method for identifying a test compound that modulates expression of a Fra-1 gene in a brain cancer cell Grant 6,884,581 - Debinski , et al. April 26, 2 | 2005-04-26 |
Nucleic acids encoding IL13 mutants Grant 6,884,603 - Debinski , et al. April 26, 2 | 2005-04-26 |
Nucleic acids encoding IL13 mutants App 20050053589 - Debinski, Waldemar ;   et al. | 2005-03-10 |
EGFR ligands and methods of use App 20030211112 - Debinski, Waldemar | 2003-11-13 |
Amino acid substitution mutants of interleukin 13 Grant 6,630,576 - Debinski October 7, 2 | 2003-10-07 |
IL-13 receptor specific chimeric proteins & uses thereof App 20030129132 - Puri, Raj K. ;   et al. | 2003-07-10 |
IL13 mutants Grant 6,576,232 - Debinski , et al. June 10, 2 | 2003-06-10 |
Antibodies that bind IL-13 mutants App 20030031666 - Debinski, Waldemar ;   et al. | 2003-02-13 |
IL-13 receptor specific chimeric proteins and uses thereof Grant 6,518,061 - Puri , et al. February 11, 2 | 2003-02-11 |
Immunotherapy using interleukin 13 receptor subunit alpha 2 App 20020197266 - Debinski, Waldemar | 2002-12-26 |
Cancer immunotherapy App 20020182219 - Debinski, Waldemar ;   et al. | 2002-12-05 |
VEGF-D expression in brain cancer App 20020164624 - Debinski, Waldemar ;   et al. | 2002-11-07 |
Nucleic acids encoding IL13 mutants App 20020159972 - Debinski, Waldemar ;   et al. | 2002-10-31 |
FRA -1 expression in brain cancer App 20020151457 - Debinski, Waldemar ;   et al. | 2002-10-17 |
Amino acid substitution mutants of interleukin 13 App 20020119120 - Debinski, Waldemar | 2002-08-29 |
Compositions and methods for specifically targeting tumors Grant 6,428,788 - Debinski , et al. August 6, 2 | 2002-08-06 |
Characterizing a brain tumor App 20020031492 - Debinski, Waldemar | 2002-03-14 |
Method For Diagnosing, Imaging, And Treating Tumors Using Restrictive Receptor For Interleukin 13 App 20010053371 - DEBINSKI, WALDEMAR ;   et al. | 2001-12-20 |
Mutagenized IL 13-based chimeric molecules Grant 6,296,843 - Debinski October 2, 2 | 2001-10-02 |
IL-13 receptor specific chimeric proteins Grant 5,919,456 - Puri , et al. July 6, 1 | 1999-07-06 |
IL-13 receptor specific chimeric proteins and uses thereof Grant 5,614,191 - Puri , et al. March 25, 1 | 1997-03-25 |
Recombinant chimeric proteins deliverable across cellular membranes into cytosol of target cells Grant 5,328,984 - Pastan , et al. July 12, 1 | 1994-07-12 |
NCAGE Code | 4VU39 | DEBINSKI, WALDEMAR |
CAGE Code | 4VU39 | DEBINSKI, WALDEMAR |
DUNS | 807418327 | DEBINSKI, WALDEMAR |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.